TABLE 4

Summary of Moderator Analyses for Total Sleep Time

CharacteristickbQ RegressionQ Residual
Method/design characteristics
 Length of time on medication (in days)70.005Q(1) = 0.30, P = .54Q(5) = 7.27, P = .20
 Mean total dosage/day (in milligrams)3−0.07Q(1) = 0.59, P = .44Q(1) = 2.74, P = .10
 Frequency of dosage/d6−0.22Q(1) = 2.72, P = .10Q(4) = 7.56, P = .11
 Frequency of dosage/wk6−0.20Q(1) = 3.33, P = .06Q(3) = 8.53, P = .07
 No. of nights of sleep assessed70.002Q(1) = 0.02, P = .88Q(5) = 7.45, P = .19
 Method of total sleep time assessment7−0.56Q(1) = 3.14, P = .08Q(5) = 8.42, P = .13
 Stimulant medication class70.37Q(1) = 1.17, P = .28Q(5) = 7.39, P = .19
 Funding source70.26Q(1) = 0.89, P = .35Q(5) = 7.19, P = .21
Sample characteristics
 Gender70.03Q(1) = 2.34, P = .13Q(5) = 7.16, P = .21
 Age70.009Q(1) = 0.59, P = .44Q(5) = 7.20, P = .21
  • b, unstandardized regression coefficient;k, number of studies; Q Regression, homogeneity test for regression (ie, regression sum of squares); Q Residual, sum-of-squares residual (represents sampling error and random variation).